MICROB-PREDICT
@microb-predict.bsky.social
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825694.
Website: https://microb-predict.eu/
Website: https://microb-predict.eu/
The session will also be available to watch on demand on EASL Campus from Thursday, 27 November
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
EASL Campus
Continue your hepatology and liver-related disease education though our multi-disciplinary, open access eLearning platform EASL Campus. Sign up to access state-of-the-art digital courses and resources...
easlcampus.eu
November 24, 2025 at 12:05 PM
The session will also be available to watch on demand on EASL Campus from Thursday, 27 November
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
🔬 Read the original publication by Boglarka Balogh, David Tornai, Aniko Csillag et al. (2025) on behalf of the MICROB-PREDICT consortium and the PREDICT study group of the EASL-CLIF consortium: onlinelibrary.wiley.com/doi/10.1111/...
Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF
Background and Aims In cirrhosis, impaired gut mucosal immunity facilitates bacterial translocation (BT) instigating the proinflammatory cascade that exacerbates hepatic damage. The role of antibody...
onlinelibrary.wiley.com
September 23, 2025 at 12:40 PM
🔬 Read the original publication by Boglarka Balogh, David Tornai, Aniko Csillag et al. (2025) on behalf of the MICROB-PREDICT consortium and the PREDICT study group of the EASL-CLIF consortium: onlinelibrary.wiley.com/doi/10.1111/...
Both groups (placebo vs. #albumin treatment) are monitored closely regarding their liver disease & overall health. We thank the dedicated teams at all sites across Europe for their hard work in achieving this milestone. We look forward to continuing this progress toward completing the ALB-TRIAL! 💪
August 27, 2025 at 12:41 PM
Both groups (placebo vs. #albumin treatment) are monitored closely regarding their liver disease & overall health. We thank the dedicated teams at all sites across Europe for their hard work in achieving this milestone. We look forward to continuing this progress toward completing the ALB-TRIAL! 💪
The ALB-TRIAL is a double-blinded, placebo-controlled clinical trial to see if a new biomarker can be used to predict which patients with #cirrhosis + #ascites benefit most from long-term human #albumin infusion. Moving towards personalised treatment, less complications & lower risk of death. 🔬⚕️🩺
August 27, 2025 at 12:41 PM
The ALB-TRIAL is a double-blinded, placebo-controlled clinical trial to see if a new biomarker can be used to predict which patients with #cirrhosis + #ascites benefit most from long-term human #albumin infusion. Moving towards personalised treatment, less complications & lower risk of death. 🔬⚕️🩺
May 10, 2025 at 10:01 AM